# Clinical Study to Evaluate the Safety and Efficacy of Switching to Tenofovir Disoproxil From Tenofovir Disoproxil Fumarate in Patients With Chronic Hepatitis B

> **NCT05286346** · PHASE4 · COMPLETED · sponsor: **Samjin Pharmaceutical Co., Ltd.** · enrollment: 113 (actual)

## Conditions studied

- Chronic Hepatitis b

## Interventions

- **DRUG:** Tenofovir disoproxil 245mg
- **DRUG:** Tenofovir disoproxil fumarate 300mg

## Key facts

- **NCT ID:** NCT05286346
- **Lead sponsor:** Samjin Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-12
- **Primary completion:** 2020-08-10
- **Final completion:** 2020-08-10
- **Target enrollment:** 113 (ACTUAL)
- **Last updated:** 2025-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05286346

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05286346, "Clinical Study to Evaluate the Safety and Efficacy of Switching to Tenofovir Disoproxil From Tenofovir Disoproxil Fumarate in Patients With Chronic Hepatitis B". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05286346. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*